# US Coronary Stents Market

> US Coronary Stents Market Research Report: Size, Share, Trend Analysis By Types (Drug-Eluting Stents, Bare-Metal Stents, Bio absorbable Stents), By Material (Metal Stents, Polymer Stents, Coated Stents), By End Use (Hospitals, Ambulatory Surgical Centers, Cardiac Catheterization Labs) and By Applications (Coronary Artery Disease, Peripheral Artery Disease, Acute Myocardial Infarction) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 3.04%
- **2024:** $ 1,621.9 Million
- **2025:** $ 1,671.21 Million
- **2035:** $ 2,254.74 Million
- **Key Players:** Abbott Laboratories (US), Boston Scientific Corporation (US), Medtronic plc (IE), B. Braun Melsungen AG (DE), Terumo Corporation (JP), Cardinal Health, Inc. (US), Johnson & Johnson (US), Cook Medical Incorporated (US)

**Report ID:** MRFR/MED/14524-HCR · **Pages:** 100 · **Author:** Rahul Gotadki · **Last Updated:** April 24, 2026

**URL:** https://www.marketresearchfuture.com/reports/us-coronary-stents-market-16051

---

## Market Summary

## **US Coronary Stents Market Overview**

As per MRFR analysis, the US Coronary Stents Market Size was estimated at 1.58 (USD Billion) in 2023. The US Coronary Stents Market Industry is expected to grow from 1.65(USD Billion) in 2024 to 2.3 (USD Billion) by 2035. The US Coronary Stents Market CAGR (growth rate) is expected to be around 3.065% during the forecast period (2025 - 2035).

## **Key US Coronary Stents Market Trends Highlighted**

The US Coronary Stents Market is witnessing significant trends driven by advancements in medical technology and increasing prevalence of cardiovascular diseases. Key market drivers include the rising aging population and higher rates of lifestyle-related health issues such as obesity and diabetes, which contribute to a growing demand for interventional procedures. With more people than ever relying on coronary stents for treating coronary artery disease, innovations in stent designs, including biodegradable materials and drug-eluting stents, are becoming prominent. These advancements not only enhance patient outcomes but also address concerns around long-term safety and effectiveness.

Opportunities in the US market include the potential for expanding telehealth services and remote patient monitoring. The integration of these technologies can streamline the post-procedure care process for patients who have undergone stent implantation, creating a more efficient healthcare system. Furthermore, the increasing focus on personalized medicine paves the way for tailored stent solutions, which can better meet individual patient needs.

In recent times, the emphasis has shifted toward minimally invasive procedures, and the use of coronary stent systems that facilitate quicker recovery times is on the rise. Coupled with a growing awareness among patients about treatment options, these trends are reshaping the approach towards cardiovascular interventions. Hospitals and healthcare providers are also focusing on cost-effective treatments, enabling wider access to these critical devices. As regulatory pathways become more accommodating, the innovation landscape continues to evolve, highlighting the dynamic nature of the US Coronary Stents Market.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **US Coronary Stents Market Drivers**

### **Rising Incidence of Cardiovascular Diseases**

The increasing prevalence of cardiovascular diseases in the United States is a significant driver for the US Coronary Stents Market Industry. According to the American Heart Association, heart disease is the leading cause of death for both men and women in the US, with approximately 697,000 deaths in 2022. As the population ages, the number of individuals diagnosed with conditions such as coronary artery disease is expected to rise.

Furthermore, the Centers for Disease Control and Prevention (CDC) reports that about 18.2 million adults in the US suffer from coronary artery disease (CAD), an increase of approximately 3 million over the last decade. This rise in CAD cases drives the need for effective treatment solutions, including coronary stents. The increasing focus of healthcare providers, such as the American College of Cardiology, on developing and promoting innovative stenting procedures also contributes to market growth by encouraging adoption among patients and providers alike.

### **Technological Advancements in Stent Development**

Innovative technological advancements in stent design and materials are pivotal in propelling the US Coronary Stents Market Industry. The introduction of bioresorbable stents, which dissolve over time, has garnered increased attention due to their potential to minimize adverse long-term effects and improve patient outcomes. The FDA's approval of several revolutionary stent technologies, including the use of drug-eluting stents and bioengineered materials, demonstrates the evolving landscape of coronary interventions.

As more healthcare institutions adopt these advanced solutions, patient acceptance and demand will increase, fostering growth in the market. The ongoing Research and Development initiatives spearheaded by major health organizations and cardiac device manufacturers further highlight the commitment to improving stenting technology.

### **Increasing Government and Private Investments in Healthcare**

Investment in healthcare, particularly in cardiovascular research and interventions, plays a crucial role in shaping the US Coronary Stents Market Industry. The US government, through initiatives like the National Institutes of Health (NIH), allocates significant funds towards research aimed at improving cardiovascular health. The NIH's investments in cardiovascular research have grown steadily, with the agency appropriating around $3 billion for heart disease research in the latest fiscal year.

Additionally, private sector investments and collaborations among healthcare companies facilitate rapid advancements in coronary stent technologies, contributing to the overall growth of the market. This collaborative effort between public and private entities significantly enhances the resources and expertise available within the cardiovascular stenting field.

### **Aging Population and Lifestyle Changes**

The aging population in the United States is a critical driver of the US Coronary Stents Market Industry. With the US Census Bureau reporting that the population aged 65 and older is expected to grow from 54 million in 2020 to 80 million by 2040, the demand for cardiovascular interventions will significantly escalate. Concurrently, lifestyle changes such as increased prevalence of obesity, diabetes, and sedentary behaviour further contribute to heart-related issues.

The CDC indicates that obesity rates have doubled in the last three decades, with 42.4% of adults classified as obese in 2020. This shift in lifestyle habits directly correlates with an increased risk of coronary artery diseases, leading to a higher need for coronary stenting procedures. As healthcare systems adjust to accommodate this demographic shift, the demand for effective treatment solutions like coronary stents will naturally rise.

## **US Coronary Stents Market Segment Insights**

### **Coronary Stents Market Type Insights**

The US Coronary Stents Market has shown significant growth and evolution in its Type segmentation, particularly focusing on Drug-Eluting Stents, Bare-Metal Stents, and Bioabsorbable Stents. Drug-Eluting Stents have become increasingly prominent due to their ability to release medication that inhibits the growth of scar tissue within the artery, effectively reducing the incidence of restenosis, which has historically been a critical challenge in coronary interventions. This type of stent is characterized by advanced technology and a growing preference among physicians, primarily due to its efficacy in managing coronary artery disease.

Bare-Metal Stents, while being the original form of coronary stenting, continue to play a crucial role in the market, primarily due to their cost-effectiveness and straightforward design. They serve as a foundational technology, particularly in cases where patients may not require long-term medication or have a higher risk of complications associated with drug-eluting technologies. These stents are often utilized in scenarios where timely intervention is paramount and can be essential for effective treatment in an acute clinical setting.

In contrast, Bioabsorbable Stents represent a newer frontier in coronary intervention, aimed at providing temporary support to the arterial wall before being absorbed by the body. This type of stent addresses the potential long-term drawbacks associated with metal stents, aligning with the trend towards minimally invasive and patient-centric care. The appeal of bioabsorbable technology lies in its potential to reduce late adverse events and improve patient outcomes, making it a significant player in the evolving landscape of coronary interventions.

Examining these three types highlights a dynamic market driven by innovation, clinical outcomes, and patient needs. Developments in stent technology are also reflected in the increasing sophistication of coronary procedures, as healthcare providers in the US seek tools that enhance safety, efficacy, and overall patient satisfaction. Market trends indicate that as new technologies mature, they may enhance the treatment of coronary artery disease while addressing specific patient demographic and clinical needs, ultimately leading to improved healthcare delivery in the cardiovascular domain.

This segmentation is vital to understanding not just the current US Coronary Stents Market statistics, but also the future direction of the industry, where advancements will likely shape therapeutic strategies and patient care paradigms.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **Coronary Stents Market Material Insights**

The US Coronary Stents Market, particularly focusing on the Material segment, showcases a diverse array of options tailored to meet various patient needs and clinical applications. This segment includes Metal Stents, Polymer Stents, and Coated Stents, each playing a pivotal role in improving patient outcomes. Metal Stents are well-established due to their strength and durability, often providing immediate structural support to narrowed coronary arteries. Polymer Stents, known for their biocompatibility, offer enhanced flexibility and are gaining traction in the market due to advancements in materials science.

Coated Stents, which are designed to release therapeutic agents, address issues like restenosis, making them increasingly significant in long-term patient care. As the US healthcare landscape continues to evolve, trends such as the growing prevalence of cardiovascular diseases and the push for minimally invasive procedures drive the demand for innovative stent materials. The US Coronary Stents Market revenue reflects the ongoing investment in Research and Development, aimed at improving the performance and safety profiles of these medical devices.

Healthcare providers and patients alike are benefiting from improved technology and a larger variety of stent options, paving the way for better treatment outcomes and aligned patient preferences. These factors collectively shape the landscape of the US Coronary Stents Market and enhance its growth potential.

### **Coronary Stents Market End Use Insights**

The End Use segment of the US Coronary Stents Market is critical, encompassing various healthcare facilities that play a vital role in patient care. Hospitals are the predominant setting for coronary stent procedures, housing advanced technology and specialized cardiac care teams. These facilities typically offer comprehensive treatment options, further driving demand for stents due to the increased patient volume and complex cases requiring specialized interventions.

Ambulatory Surgical Centers have gained importance as they provide more cost-effective and convenient options for patients undergoing stent procedures, promoting quicker recovery times and shorter hospital stays. Meanwhile, Cardiac Catheterization Labs are essential for the execution of minimally invasive coronary interventions, enabling precise stent placements under imaging guidance. The growing prevalence of cardiovascular diseases in the US significantly fuels the US Coronary Stents Market revenue across these End Use settings. Moreover, advancements in medical technology and increasing awareness about heart health are expected to enhance the capabilities of these facilities, subsequently driving growth in this segment.

As a result, the segmentation reveals not only the diverse nature of the US Coronary Stents Market but also the interconnectedness of healthcare services that play a pivotal role in improving patient outcomes.

### **Coronary Stents Market Application Insights**

The Application segment of the US Coronary Stents Market plays a crucial role in addressing significant health concerns prevalent in the region, particularly focusing on conditions like Coronary Artery Disease, Peripheral Artery Disease, and Acute Myocardial Infarction. Coronary Artery Disease remains a leading cause of morbidity and mortality in the United States, driving the demand for effective treatment options, including stenting procedures aimed at restoring proper blood flow.

Peripheral Artery Disease is also significant, affecting millions of Americans and necessitating advancements in stent technology to improve vascular health and aid in recovery. Acute Myocardial Infarction, or heart attack, underscores the urgency for timely interventions, highlighting the importance of coronary stents in emergency care settings. The rising prevalence of these conditions, coupled with an aging population and increased awareness about cardiovascular health, propels growth within this segment. Moreover, ongoing research and development in stent innovations, such as drug-eluting options, aim to enhance patient outcomes further.

As a result, the Application segment is poised for substantial advancements, contributing significantly to overall US Coronary Stents Market growth.

## **US Coronary Stents Market Key Players and Competitive Insights**

The US Coronary Stents Market is characterized by a high level of competition among several key players, each striving to capture market share while delivering innovative solutions for patients with coronary artery disease. With an increasing prevalence of heart disease, alongside advancements in technology and materials used in stent development, companies in this sector are continuously investing in research and development to enhance the effectiveness and safety of their products. The competitive landscape is driven by factors such as product differentiation, strategic partnerships, regulatory compliance, and market accessibility.

As the population ages and healthcare awareness increases, the demand for coronary stents continues to grow, leading to more robust competition among leading firms in the market.

Medtronic has established a strong presence in the US Coronary Stents Market by leveraging its extensive portfolio of products and a solid commitment to innovation. The company is recognized for its advanced stent designs and delivery systems, which are widely adopted due to their proven efficacy and safety profiles. Medtronic’s strengths lie not only in its technological advancements but also in its ability to scale operations and optimize supply chains to meet customer demands effectively.

Moreover, their focus on collaboration with healthcare professionals enables Medtronic to stay at the forefront of clinical advancements, ensuring that their products continuously meet the evolving needs of patients and healthcare providers in the competitive landscape of the US market.

Abbott Laboratories has also carved a niche in the US Coronary Stents Market with its cutting-edge products and solutions that cater to patients suffering from coronary artery disease. The company offers a range of stents designed for diverse patient needs, including bioresorbable options that represent a significant evolution in stent technology. Abbott's competitive strengths include a strong reputation for quality, rigorous clinical testing, and a robust research agenda aimed at developing innovative products.

Additionally, Abbott has strategically pursued mergers and acquisitions to bolster its product offerings and market reach, enhancing its capabilities to respond to customer needs in this dynamic sector. Their commitment to improving patient outcomes and expanding access to their technology positions Abbott as a formidable player in the US coronary stent market.

### **Key Companies in the US Coronary Stents Market Include**

## **US Coronary Stents Market Industry Developments**

In recent months, the US Coronary Stents Market has experienced significant developments as major companies like Medtronic, Abbott Laboratories, and Boston Scientific continue to innovate with advanced stent technologies aimed at improving patient outcomes. In July 2023, Abbott inaugurated a new manufacturing facility focused on producing bioresorbable stents, positioning itself strongly in the growing segment of biodegradable devices. Meanwhile, in September 2023, Medtronic announced a strategic partnership with Gore Medical to enhance their collaborative efforts in developing innovative stenting solutions.

The market also saw a notable merger, with Boston Scientific acquiring a smaller competitor in August 2023 to expand its product portfolio and market share. Over the last couple of years, there has been a steady increase in market valuation across these companies due to the rising prevalence of coronary artery diseases and advancements in minimally invasive procedures. With the approval of new devices by the US Food and Drug Administration, the market is expected to continue its upward trajectory, driven largely by technological innovations and strategic alliances between leading manufacturers like Johnson and Johnson, Siemens, and Terumo.

## **US Coronary Stents Market Segmentation Insights**

### **Coronary Stents Market Type Outlook**

### **Coronary Stents Market Material Outlook**

### **Coronary Stents Market End Use Outlook**

### **Coronary Stents Market Application Outlook**

## Market Drivers

### Increasing Aging Population

The aging population in the US is a critical driver for the coronary stents market. As individuals age, the incidence of cardiovascular diseases tends to rise, leading to a higher demand for interventional procedures. According to recent statistics, approximately 15% of the US population is aged 65 and older, a demographic that is particularly susceptible to heart-related ailments. This demographic shift suggests a growing need for effective treatment options, including coronary stents. Furthermore, the coronary stents market is likely to experience increased sales as healthcare providers focus on addressing the needs of older patients. The combination of an aging population and the rising prevalence of heart diseases indicates a robust market potential for coronary stents in the coming years.

### Rising Healthcare Expenditure

The increasing healthcare expenditure in the US is a significant driver for the coronary stents market. As healthcare budgets expand, hospitals and healthcare facilities are more likely to invest in advanced medical technologies, including coronary stents. In 2025, healthcare spending in the US is projected to reach approximately $4 trillion, with a substantial portion allocated to cardiovascular treatments. This financial commitment indicates a favorable environment for the coronary stents market, as healthcare providers seek to enhance patient care through innovative solutions. Additionally, the rise in insurance coverage for cardiovascular procedures further supports market growth, as patients gain better access to necessary treatments. The correlation between healthcare spending and the demand for coronary stents suggests a positive outlook for the industry.

### Advancements in Medical Technology

Technological innovations play a pivotal role in shaping the coronary stents market. The introduction of drug-eluting stents and bioresorbable stents has revolutionized treatment options for patients with coronary artery disease. These advancements not only enhance the efficacy of stenting procedures but also reduce the risk of restenosis, thereby improving patient outcomes. The coronary stents market is witnessing a surge in demand for these advanced products, as they offer significant benefits over traditional stents. Market data indicates that the adoption of drug-eluting stents has increased by approximately 30% in recent years, reflecting a shift towards more effective treatment modalities. This trend suggests that ongoing research and development in stent technology will continue to drive market growth.

### Growing Awareness of Cardiovascular Health

Public awareness regarding cardiovascular health is increasingly influencing the coronary stents market. Educational campaigns and initiatives aimed at promoting heart health have led to a greater understanding of the risks associated with cardiovascular diseases. As individuals become more informed, they are more likely to seek medical attention for symptoms related to heart conditions. This heightened awareness is driving demand for diagnostic and interventional procedures, including the use of coronary stents. The coronary stents market is benefiting from this trend, as healthcare providers respond to the growing need for effective treatment options. Furthermore, the emphasis on preventive care and early intervention is likely to sustain market growth, as patients are encouraged to prioritize their cardiovascular health.

### Regulatory Support for Innovative Treatments

Regulatory bodies in the US are increasingly supportive of innovative treatments in the coronary stents market. The expedited approval processes for new stent technologies, such as bioresorbable stents, reflect a commitment to enhancing patient care. This regulatory environment encourages manufacturers to invest in research and development, leading to the introduction of advanced products that meet evolving patient needs. The coronary stents market is poised to benefit from this supportive framework, as it fosters innovation and competition among manufacturers. Additionally, the potential for faster market entry for new technologies may lead to increased availability of cutting-edge stent options for healthcare providers. This regulatory landscape suggests a promising future for the coronary stents market as it adapts to the demands of modern medicine.

## Future Outlook

The [Coronary Stents Market](https://www.marketresearchfuture.com/reports/coronary-stents-market-6938) is projected to grow at a 3.04% CAGR from 2025 to 2035, driven by technological advancements, increasing cardiovascular diseases, and rising healthcare expenditures.

**New opportunities:**

- Development of biodegradable stents for enhanced patient outcomes. Expansion of telehealth services for remote stent monitoring. Partnerships with insurance providers for bundled payment models.

By 2035, the coronary stents market is expected to achieve robust growth and innovation.

## Segment Insights

### By Type: Drug-Eluting Stents (Largest) vs. Bioabsorbable Stents (Fastest-Growing)

In the US coronary stents market, Drug-Eluting Stents continue to hold the largest market share due to their superior efficacy in reducing restenosis rates. These stents are preferred by healthcare professionals for their ability to release drugs that prevent blockage in the arteries, leading to higher adoption rates. Bare-Metal Stents also maintain a significant presence but are overshadowed by the advanced technology of drug-eluting options. 

On the other hand, Bioabsorbable Stents represent the fastest-growing segment, gaining traction for their innovative design that naturally degrades over time. Their appeal lies in the prospect of fewer long-term complications and reduced need for prolonged medication, making them increasingly popular among both patients and physicians. This growth is further accelerated by advancements in biomaterials and clinical evidence supporting their effectiveness.

Stent Type: Drug-Eluting (Dominant) vs. Bioabsorbable (Emerging)

Drug-Eluting Stents are currently the dominant choice in the market, known for their advanced technology and ability to significantly lower the risk of restenosis through localized drug delivery. They are often favored for complex procedures and among patients with higher risk factors. In contrast, Bioabsorbable Stents, which gradually dissolve after fulfilling their purpose, represent an emerging segment that is rapidly gaining acceptance. These stents alleviate concerns regarding long-term foreign body presence in the arteries, appealing to a growing patient demographic that prioritizes safety and comfort in their treatment options. As innovation continues, both segments are expected to influence the overall landscape of the coronary stents market.

### By Material: Metal Stents (Largest) vs. Coated Stents (Fastest-Growing)

In the US coronary stents market, the distribution of market share among different material segments reveals that metal stents dominate due to their established efficacy and widespread use. They account for a significant share of the market, benefitting from a long history of clinical success. Meanwhile, coated stents are gaining traction, attributed to advancements in technology and increased focus on patient outcomes, which positions them as the fastest-growing segment within the market.

The growth trends in the material segment are influenced by various factors. Metal stents continue to be favored for their durability and ease of implantation, while coated stents are rapidly emerging due to their capacity to reduce restenosis rates through drug delivery mechanisms. The rising incidence of coronary artery diseases pushes demand for innovative stent solutions, indicating a dynamic shift towards the adoption of coated stents in the near future.

Metal Stents (Dominant) vs. Coated Stents (Emerging)

Metal stents, recognized for their strength and reliability, hold a dominant position in the US coronary stents market. Their robust design and proven track record contribute to high acceptance rates among healthcare professionals. In contrast, coated stents are an emerging solution that offers unique benefits, including the release of therapeutic agents to minimize blockage recurrence. As healthcare providers seek more effective interventions for complex cases, the shift towards coated stents is expected to accelerate, driven by ongoing research and positive clinical outcomes, ensuring a competitive landscape between these two segments.

### By End Use: Hospitals (Largest) vs. Ambulatory Surgical Centers (Fastest-Growing)

In the US coronary stents market, the distribution of end use segments reveals that hospitals dominate the market, capturing a significant share due to their capacity for complex procedures and comprehensive patient care. Ambulatory surgical centers, while smaller in share, are rapidly gaining traction as a preferred option for less invasive procedures, contributing to their growing presence in the market. The growth of cardiac catheterization labs also highlights the diversification of end-use settings in the market, catering to specific patient needs and procedural efficiencies.

The growth trends for these segments indicate a strong shift towards outpatient care, with ambulatory surgical centers witnessing an increase due to the rising preference for minimally invasive procedures and shorter recovery times. Hospitals are also adapting, focusing on enhancing their services and infrastructure to maintain dominance. Technological advancements in stent designs and materials are crucial drivers across all segments, ensuring better patient outcomes and fostering further growth.

Hospitals (Dominant) vs. Ambulatory Surgical Centers (Emerging)

Hospitals play a dominant role in the US coronary stents market, leveraging their extensive resources, skilled personnel, and advanced technologies to provide comprehensive cardiac care. They are equipped to handle complex cases and offer postoperative care, making them the preferred choice for high-risk patients. In contrast, ambulatory surgical centers represent an emerging segment that is increasingly appealing due to their ability to perform elective procedures with shorter waiting times and reduced costs. These facilities focus on outpatient services, catering to a growing population that seeks efficient and less invasive treatment options. As healthcare evolves, both segments are expected to adapt and thrive, albeit through distinct operating models and patient engagement strategies.

### By Application: Coronary Artery Disease (Largest) vs. Acute Myocardial Infarction (Fastest-Growing)

In the US coronary stents market, the application of coronary artery disease holds a significant share, reflecting the high prevalence of coronary heart conditions. Peripheral artery disease follows, while acute myocardial infarction is emerging as a vital segment with an increasing focus on rapid intervention and treatment options. The distribution of market shares illustrates a clear dominance of coronary artery disease, highlighting the need for effective stent solutions.

Growth trends indicate that while coronary artery disease remains the largest segment, acute myocardial infarction is witnessing the fastest growth driven by advancements in medical technology and an increasing awareness of heart health. Factors contributing to this trend include the growing aging population, lifestyle changes leading to higher incidences of myocardial infarction, and improved healthcare infrastructure supporting timely emergency responses, leading to enhanced stenting solutions.

Coronary Artery Disease: Dominant vs. Acute Myocardial Infarction: Emerging

Coronary artery disease represents the dominant segment in the application area of the US coronary stents market, characterized by a comprehensive range of stenting solutions catering to chronic conditions. This segment benefits from established treatment protocols and a robust market presence due to the high volume of procedures performed. In contrast, the acute myocardial infarction segment is emerging rapidly, driven by innovative technologies that promote timely intervention. This segment is becoming increasingly crucial as medical professionals focus on urgent cases that require immediate stenting solutions, highlighting the shift in market dynamics towards acute care scenarios.

## Competitive Benchmarking

The coronary stents market is characterized by a competitive landscape that is both dynamic and multifaceted. Key growth drivers include an increasing prevalence of cardiovascular diseases, advancements in stent technology, and a growing emphasis on minimally invasive procedures. Major players such as Abbott Laboratories (US), Boston Scientific Corporation (US), and Medtronic plc (IE) are strategically positioned to leverage these trends. Abbott Laboratories (US) focuses on innovation, particularly in drug-eluting stents, while Boston Scientific Corporation (US) emphasizes partnerships to enhance its product offerings. Medtronic plc (IE) is actively pursuing regional expansion, particularly in emerging markets, which collectively shapes a competitive environment that is increasingly reliant on technological advancements and strategic collaborations. In terms of business tactics, companies are localizing manufacturing and optimizing supply chains to enhance efficiency and reduce costs. The market structure appears moderately fragmented, with several key players exerting considerable influence. This fragmentation allows for a diverse range of products and innovations, yet the collective strength of these companies fosters a competitive atmosphere where differentiation is crucial. In October 2025, Abbott Laboratories (US) announced the launch of its latest drug-eluting stent, which incorporates advanced polymer technology aimed at improving patient outcomes. This strategic move is significant as it not only reinforces Abbott's commitment to innovation but also positions the company to capture a larger market share amidst increasing competition. The introduction of this product is likely to enhance patient safety and efficacy, thereby solidifying Abbott's reputation as a leader in the coronary stents market. In September 2025, Boston Scientific Corporation (US) entered into a strategic partnership with a leading telehealth provider to integrate remote monitoring capabilities into its stent offerings. This initiative reflects a growing trend towards digital health solutions, enabling better patient management and follow-up care. By embracing digital transformation, Boston Scientific is not only enhancing its product portfolio but also addressing the evolving needs of healthcare providers and patients alike. In August 2025, Medtronic plc (IE) expanded its manufacturing capabilities in the US by investing $50 million in a new facility dedicated to the production of coronary stents. This investment underscores Medtronic's commitment to meeting the increasing demand for stents while ensuring high-quality production standards. The establishment of this facility is expected to enhance supply chain reliability and reduce lead times, positioning Medtronic favorably in a competitive market. As of November 2025, current trends in the coronary stents market include a pronounced shift towards digitalization, sustainability, and the integration of artificial intelligence (AI) in product development. Strategic alliances are increasingly shaping the landscape, allowing companies to pool resources and expertise. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This shift may redefine market dynamics, compelling companies to invest in R&D and collaborative ventures to maintain a competitive edge.

## Recent News & Developments

In recent months, the US Coronary Stents Market has experienced significant developments as major companies like Medtronic, Abbott Laboratories, and Boston Scientific continue to innovate with advanced stent technologies aimed at improving patient outcomes. In July 2023, Abbott inaugurated a new manufacturing facility focused on producing bioresorbable stents, positioning itself strongly in the growing segment of biodegradable devices. Meanwhile, in September 2023, Medtronic announced a strategic partnership with Gore Medical to enhance their collaborative efforts in developing innovative stenting solutions.

The market also saw a notable merger, with Boston Scientific acquiring a smaller competitor in August 2023 to expand its product portfolio and market share. Over the last couple of years, there has been a steady increase in market valuation across these companies due to the rising prevalence of coronary artery diseases and advancements in minimally invasive procedures. With the approval of new devices by the US Food and Drug Administration, the market is expected to continue its upward trajectory, driven largely by technological innovations and strategic alliances between leading manufacturers like Johnson and Johnson, Siemens, and Terumo.

## Report Scope

| MARKET SIZE 2024 | 1621.9(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 1671.21(USD Million) |
| MARKET SIZE 2035 | 2254.74(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 3.04% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Abbott Laboratories (US), Boston Scientific Corporation (US), Medtronic plc (IE), B. Braun Melsungen AG (DE), Terumo Corporation (JP), Cardinal Health, Inc. (US), Johnson & Johnson (US), Cook Medical Incorporated (US) |
| Segments Covered | Type, Material, End Use, Application |
| Key Market Opportunities | Advancements in biodegradable stents present new avenues for innovation in the coronary stents market. |
| Key Market Dynamics | Technological advancements and regulatory changes drive innovation and competition in the coronary stents market. |
| Countries Covered | US |

## Frequently Asked Questions

**Q: What was the overall market valuation of the US coronary stents market in 2024?**
A: The overall market valuation was $1621.9 Million in 2024.

**Q: What is the projected market valuation for the US coronary stents market by 2035?**
A: The projected valuation for 2035 is $2254.74 Million.

**Q: What is the expected CAGR for the US coronary stents market during the forecast period 2025 - 2035?**
A: The expected CAGR for the market during the forecast period is 3.04%.

**Q: Which type of stents had the highest valuation in 2024?**
A: Drug-Eluting Stents had the highest valuation, ranging from $800.0 Million to $1100.0 Million.

**Q: What are the projected valuations for Bare-Metal Stents by 2035?**
A: The projected valuations for Bare-Metal Stents are expected to range from $600.0 Million to $800.0 Million.

**Q: Which companies are considered key players in the US coronary stents market?**
A: Key players include Abbott Laboratories, Boston Scientific Corporation, Medtronic plc, and Johnson & Johnson.

**Q: What was the valuation range for Bioabsorbable Stents in 2024?**
A: The valuation range for Bioabsorbable Stents was $221.9 Million to $354.74 Million.

**Q: What is the expected market performance for Cardiac Catheterization Labs by 2035?**
A: The expected market performance for Cardiac Catheterization Labs is projected to range from $621.9 Million to $904.74 Million.

**Q: How do the valuations for Polymer Stents compare to Metal Stents in 2024?**
A: In 2024, Polymer Stents had a valuation range of $500.0 Million to $700.0 Million, while Metal Stents ranged from $600.0 Million to $800.0 Million.

**Q: What application had the highest valuation in the US coronary stents market in 2024?**
A: Coronary Artery Disease had the highest valuation, ranging from $800.0 Million to $1100.0 Million.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-coronary-stents-market-16051*